Probitas Pharma Completes Acquisition of SeraCare

September 28, 2001 — LOS ANGELES, CA — SeraCare, Inc. recently announced that Instituto Grifols, S.A., a subsidiary of Probitas Pharma, S.A., has completed its acquisition of SeraCare, Inc. for$116.5 million in cash plus the assumption of approximately $30.0 million in debt.

SeraCare also announced that at the close of business on September 24, 2001, it had effected the spin-off of its distribution and manufacturing division, SeraCare Life Sciences, Inc.

Pursuant to the terms of the Probitas Pharma acquisition, SeraCare stockholders of record as of the close of business on September 24, 2001 will receive a cash payment of $6.8513 for every share of SeraCare held.

“We are pleased to have completed our merger with Probitas Pharma and the spin-off of SeraCare Life Sciences, transactions which we believe delivered substantial value to SeraCare shareholders,” said Barry Plost, president and CEO of SeraCare, and CEO of SeraCare Life Sciences.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.